You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
樂普醫療(300003.SZ):兩款醫用血管造影X射線機獲NMPA註冊批准
格隆匯 02-06 20:42

格隆匯2月6日丨樂普醫療(300003.SZ)公佈,公司於今日獲悉全資子公司樂普(北京)醫療裝備有限公司(樂普裝備)自主研製的兩款醫用血管造影X射線機獲得國家食品藥品監督管理局註冊批准,型號分別為:Vicor-CV RobinC/Vicor-CV RobinF型醫用血管造影X射線機;Vicor-CV SWIFT型醫用血管造影X射線機。

血管造影技術現已廣泛應用於臨牀治療,是心腦血管以及外周血管介入診療的必備設備。兩款新型醫用血管造影X射線機可選多種機架形式(落地式和懸吊式),適用醫院不同場地,並配有先進的影像鏈X射線成像裝置。通過關鍵部件升級,適配旋轉造影和步進造影功能,設備性能獲得大幅提升,使診斷更加精準,操作更加便利,手術更加高效。新一代大尺寸、16bit超高清平板探測器,結合核心優質圖像算法,具有圖像分辨率高、灰階度廣、動態範圍廣、信息量大等特點,能夠顯著提高血管造影診斷的準確率,是國內外知名醫療機構進行血管介入診療普遍應用的機型。

上述兩款設備作為公司醫療器械板塊的重要產品,將實現公司血管造影設備在高端醫療機構的覆蓋,同時將進一步促進縣級醫院介入導管室和心血管科室合作共建心臟中心的建設進程,進一步提高基層醫療機構的介入診療水平。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account